SIGMAR1
MOLECULAR TARGETsigma non-opioid intracellular receptor 1
SIGMAR1 (sigma non-opioid intracellular receptor 1) is targeted by 24 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting SIGMAR1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Nalorphine | 2.20 | 8 |
| 2 | N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide [Supplementary Concept] | 1.61 | 4 |
| 3 | Buspirone | 1.39 | 3 |
| 4 | Fluvoxamine | 1.39 | 3 |
| 5 | Fluoxetine | 1.10 | 2 |
| 6 | Progesterone | 1.10 | 2 |
| 7 | Sertraline | 1.10 | 2 |
| 8 | Astemizole Antihistamine drug now withdrawn from | 1.10 | 2 |
| 9 | Dextromethorphan Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of | 1.10 | 2 |
| 10 | Dextrorphan Dextro form of levorphanol. It acts as | 1.10 | 2 |
| 11 | Dihydroergotamine | 1.10 | 2 |
| 12 | Fentanyl | 1.10 | 2 |
| 13 | Ibogaine | 1.10 | 2 |
| 14 | Ritodrine | 1.10 | 2 |
| 15 | Timolol | 1.10 | 2 |
| 16 | Tolterodine Tartrate | 1.10 | 2 |
| 17 | Testosterone | 0.69 | 1 |
| 18 | Butaclamol | 0.69 | 1 |
| 19 | Dolutegravir | 0.69 | 1 |
| 20 | hydantoins | 0.69 | 1 |
| 21 | Levorphanol | 0.69 | 1 |
| 22 | Ondansetron | 0.69 | 1 |
| 23 | Phentolamine | 0.69 | 1 |
| 24 | Pramipexole | 0.69 | 1 |
About SIGMAR1 as a Drug Target
SIGMAR1 (sigma non-opioid intracellular receptor 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 24 compounds with documented SIGMAR1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
SIGMAR1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.